CETP Trials Still Inhibited As Torcetrapib Results Fail To Illuminate Outcomes

The much anticipated results from Pfizer's failed torcetrapib trials did little to illuminate the cause of adverse outcomes in cholesteryl ester transfer protein inhibition, leaving an expectant industry with a charge to start more clinical trials